Aptevo Therapeutics Inc (APVO)

$1.43 -0.02 (-1.38%)
Market Cap 4.70M
Revenue (ttm) 0.00
Net Income (ttm) -24.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 844,800
Avg Vol 5,476,006
Day's Range N/A - N/A
Shares Out 3.29M
Stochastic %K 11%
Beta 5.87
Analysts Sell
Price Target $21.00

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 838 0500
Fax: 206 838 0503
Address:
2401 4th Avenue, Suite 1050, Seattle, United States
Retail_Warrior
Retail_Warrior Oct. 5 at 3:14 AM
$APVO Is this junk or extremely undervalued?
0 · Reply
ChartChartist
ChartChartist Oct. 5 at 1:28 AM
$PAVS $3 - $5 when compliance then news release. Its locked. The rest is shorts playing small. $APVO 1.4 nice $ENVB accumulation $ISPC $1 alert set
0 · Reply
Goldwave9
Goldwave9 Oct. 4 at 1:39 PM
$APVO Looks like a real loser, right? Yeah, a real low float, high beta huge news loser that's right in the zone for institutions.
1 · Reply
doodledo77
doodledo77 Oct. 3 at 8:56 PM
$APVO 😉
0 · Reply
doodledo77
doodledo77 Oct. 3 at 7:42 PM
$APVO next week👀👀👀😉😉😉
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:38 PM
$FRGT $COKE $APVO $DGLY Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 3 at 6:39 PM
$APVO Data update is October 9th.
0 · Reply
MarkHuston
MarkHuston Oct. 3 at 6:36 PM
$APVO I can’t believe there are dipsht shirts that haven’t closed their positions??? 🥴
0 · Reply
alien7180
alien7180 Oct. 3 at 6:28 PM
$APVO BOA likely filed the Form 3 for 27 shares due to temporary control over a larger number of Aptevo Therapeutics shares (possibly via stock borrowings or other financial arrangements), which triggered the 10% ownership reporting requirement. The small number of shares directly reported may reflect a snapshot of their holdings or a conservative approach to SEC compliance. For precise details on their ownership calculations or specific transactions, further SEC filings (like a Schedule 13D or 13G, if applicable) or additional context from BOA would be needed.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 3 at 6:24 PM
$APVO lol 27 shares? That has to be a typo
0 · Reply
Latest News on APVO
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 16, 2025, 8:30 AM EDT - 18 days ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Sep 4, 2025, 8:45 AM EDT - 4 weeks ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 13, 2025, 8:05 AM EDT - 7 weeks ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aug 11, 2025, 8:05 AM EDT - 7 weeks ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 11:30 AM EDT - 3 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:55 AM EDT - 3 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 20, 2025, 8:01 AM EDT - 3 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 1:34 PM EDT - 3 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 11:37 AM EDT - 3 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 10:52 AM EDT - 3 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 18, 2025, 8:01 AM EDT - 3 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Participating in the BIO International Convention

Jun 13, 2025, 8:05 AM EDT - 4 months ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025, 8:05 AM EDT - 4 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 15, 2025, 8:05 AM EDT - 5 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 8, 2025, 8:45 AM EDT - 5 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 22, 2025, 4:05 PM EDT - 5 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 5 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 6 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 6 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 20, 2025, 8:35 AM EDT - 7 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 18, 2025, 8:05 AM EDT - 7 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Aptevo to Participate in March Conferences

Mar 6, 2025, 8:00 AM EST - 7 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 15, 2025, 6:59 PM EST - 8 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Feb 14, 2025, 8:05 AM EST - 8 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Jan 15, 2025, 8:00 AM EST - 9 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 12:50 PM EST - 10 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 12, 2024, 9:00 AM EST - 10 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Dec 4, 2024, 8:35 AM EST - 10 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 29, 2024, 9:55 AM EST - 11 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 26, 2024, 8:35 AM EST - 11 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 22, 2024, 8:35 AM EST - 11 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 20, 2024, 8:35 AM EST - 11 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 11, 2024, 8:15 AM EST - 11 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 8:05 AM EST - 11 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 5, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Mar 4, 2024, 9:00 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Nov 14, 2023, 8:05 AM EST - 2 years ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Aptevo to Present at Bio-Europe Conference

Nov 1, 2023, 7:45 AM EDT - 2 years ago

Aptevo to Present at Bio-Europe Conference

Retail_Warrior
Retail_Warrior Oct. 5 at 3:14 AM
$APVO Is this junk or extremely undervalued?
0 · Reply
ChartChartist
ChartChartist Oct. 5 at 1:28 AM
$PAVS $3 - $5 when compliance then news release. Its locked. The rest is shorts playing small. $APVO 1.4 nice $ENVB accumulation $ISPC $1 alert set
0 · Reply
Goldwave9
Goldwave9 Oct. 4 at 1:39 PM
$APVO Looks like a real loser, right? Yeah, a real low float, high beta huge news loser that's right in the zone for institutions.
1 · Reply
doodledo77
doodledo77 Oct. 3 at 8:56 PM
$APVO 😉
0 · Reply
doodledo77
doodledo77 Oct. 3 at 7:42 PM
$APVO next week👀👀👀😉😉😉
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:38 PM
$FRGT $COKE $APVO $DGLY Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 3 at 6:39 PM
$APVO Data update is October 9th.
0 · Reply
MarkHuston
MarkHuston Oct. 3 at 6:36 PM
$APVO I can’t believe there are dipsht shirts that haven’t closed their positions??? 🥴
0 · Reply
alien7180
alien7180 Oct. 3 at 6:28 PM
$APVO BOA likely filed the Form 3 for 27 shares due to temporary control over a larger number of Aptevo Therapeutics shares (possibly via stock borrowings or other financial arrangements), which triggered the 10% ownership reporting requirement. The small number of shares directly reported may reflect a snapshot of their holdings or a conservative approach to SEC compliance. For precise details on their ownership calculations or specific transactions, further SEC filings (like a Schedule 13D or 13G, if applicable) or additional context from BOA would be needed.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 3 at 6:24 PM
$APVO lol 27 shares? That has to be a typo
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 3 at 6:12 PM
$APVO
0 · Reply
TheKingBear
TheKingBear Oct. 3 at 5:16 PM
$APVO zero movement. Boring.
0 · Reply
JBRUN
JBRUN Oct. 3 at 2:27 PM
$APVO hopefully will turn around soon
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 3 at 2:10 PM
$APVO Manipulation everyday
1 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:47 AM
$COKE $APVO $DGLY $FAST .
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 2 at 8:21 PM
$APVO In 2021 they had an unsolicited buyout offer for $50 per share. Seem like their decision not to sell wasn't the best.
1 · Reply
MexaTraders
MexaTraders Oct. 2 at 8:16 PM
Ticker ASTC is starting to move. 6.40$ break could send ASTC into a potential HALT-up or squeeze. It is breaking out and starting its 300% run now! Can we see a massive run of ASTC into close? Micro float Squeezer is making a move! $LASE $APVO $PBM $RAYA !!
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:41 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $APVO $DGLY $FAST $DFDV 🔥
0 · Reply
JBRUN
JBRUN Oct. 2 at 5:28 PM
$APVO getting some traction
0 · Reply
mbracing113
mbracing113 Oct. 2 at 5:13 PM
$APVO huge wall sitting on $1.46
0 · Reply
mbracing113
mbracing113 Oct. 2 at 5:05 PM
$APVO 1.5 million shares traded at $1.45
0 · Reply
AlwaysBullish99
AlwaysBullish99 Oct. 2 at 4:13 PM
$APVO Whose the Wale?
2 · Reply